

**EFFECTIVE DATE:** 10|01|2015  
**POLICY LAST UPDATED:** 05|21|2020

## OVERVIEW

Neuromuscular electrical stimulation (NMES) involves the use of a device that transmits an electrical impulse to the skin over selected muscle groups by way of electrodes. There are two broad categories of these devices, NMES and functional electrical stimulation (FES). NMES stimulates the muscle when the patient is in a resting state to treat muscle atrophy. FES is used to enhance functional activity of neurologically impaired patients. FES is used to enhance the ability in spinal cord injury (SCI) patients to walk. These devices are surface units that use electrical impulses to activate paralyzed or weak muscles in precise sequence.

## MEDICAL CRITERIA

### BlueCHiP for Medicare

#### Spinal Cord Injury

FES for walking is covered in SCI patients when all of the criteria listed below is met:

- Persons with intact lower motor units (L1 and below) (both muscle and peripheral nerve);
- Persons with muscle and joint stability for weight bearing at upper and lower extremities that can demonstrate balance and control to maintain an upright support posture independently;
- Persons that demonstrate brisk muscle contraction to NMES and have sensory perception electrical stimulation sufficient for muscle contraction;
- Persons that possess high motivation, commitment, and cognitive ability to use such devices for walking;
- Persons that can transfer independently and can demonstrate independent standing tolerance for at least 3 minutes;
- Persons that can demonstrate hand and finger function to manipulate controls;
- Persons with at least 6-month post recovery spinal cord injury and restorative surgery;
- Persons without hip and knee degenerative disease and no history of long bone fracture secondary to osteoporosis; and
- Persons who have demonstrated a willingness to use the device long-term.

#### Muscle Atrophy

NMES for the treatment of muscle atrophy is covered when one of the criteria below is met:

- Treatment of disuse atrophy where nerve supply to the muscle is intact, including;
  - Brain, spinal cord and peripheral nerves, and
  - Other non-neurological reasons for disuse atrophy. (Some examples would be casting or splinting of a limb, contracture due to scarring of soft tissue as in burn lesions, and hip replacement surgery until orthotic training begins.)

#### Commercial Products

Not applicable

## **PRIOR AUTHORIZATION**

### **BlueCHiP for Medicare**

Prior authorization is required and obtained via the online tool for participating providers. See the Related Policies section.

### **Commercial Products**

Not applicable

## **POLICY STATEMENT**

### **BlueCHiP for Medicare**

Neuromuscular electrical stimulation may be considered medically necessary for the treatment of muscle atrophy when the medical criteria above is met.

Functional electrical stimulation may be considered medically necessary for the treatment of spinal cord injury when the medical criteria above is met.

NMES/FES is not covered for all other indications as there is insufficient peer reviewed scientific literature that demonstrates that the procedure/service is effective.

### **Commercial Products**

Neuromuscular stimulation (NMES/FES) is considered not medically necessary as a technique to restore function following nerve damage or nerve injury, as a technique to provide ambulation in patients with spinal cord injury; or to provide ambulation in patients with footdrop caused by congenital disorders (e.g., cerebral palsy) or nerve damage (e.g., poststroke, or in those with multiple sclerosis), as there is insufficient peer-reviewed scientific literature that demonstrates that the procedure/service is effective.

**Note:** Blue Cross & Blue Shield of Rhode Island (BCBSRI) must follow Centers for Medicare and Medicaid Services (CMS) guidelines, such as national coverage determinations or local coverage determinations for all BlueCHiP for Medicare policies. Therefore, BlueCHiP for Medicare policies may differ from Commercial products. In some instances, benefits for BlueCHiP for Medicare may be greater than what is allowed by the CMS.

## **COVERAGE**

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable durable medical equipment or not medically necessary/not covered benefits/coverage.

## **BACKGROUND**

NMES involves the use of a device that transmits an electrical impulse to the skin over selected muscle groups by way of electrodes. There are two broad categories of neuromuscular stimulation. NMES is one type of device that stimulates the muscle when the patient is in a resting state to treat muscle atrophy. The second type, FES, is used to enhance functional activity of neurologically impaired patients to treat spinal cord injuries.

Neural prosthetic devices consist of an orthotic and a microprocessor-based electronic stimulator with one or more channels for delivery of individual pulses through surface or implanted electrodes connected to the neuromuscular system. Microprocessor programs activate the channels sequentially or in unison to stimulate peripheral nerves and trigger muscle contractions to produce functionally useful movements that allow patients to sit, stand, walk, and grasp. Functional neuromuscular stimulators are closed-loop systems, which provide feedback information on muscle force and joint position, thus allowing constant modification of stimulation parameters, which are required for complex activities such as walking. These are contrasted with open-loop systems, which are used for simple tasks such as muscle strengthening alone, and typically in healthy individuals with intact neural control.

One application of functional NMES is to restore upper extremity functions such as grasp-release, forearm pronation, and elbow extension in patients with stroke, or C5 and C6 tetraplegia (quadriplegia). The Neurocontrol Freehand System is an implantable upper extremity neuroprosthesis intended to improve a patient's ability to grasp, hold, and release objects and is indicated for use in patients who are tetraplegic due to C5 or C6 spinal cord injury. The implantable Freehand System is no longer marketed in the U.S., though the company provides maintenance for devices already implanted. The Handmaster NMS I (neuromuscular stimulator) is another device that uses surface electrodes and is purported to provide hand active range of motion and function for patients with stroke or C5 tetraplegia.

Other neural prosthetic devices have been developed for functional NMES in patients with footdrop. Footdrop is weakness of the foot and ankle that causes reduced dorsiflexion and difficulty with ambulation. It can have various causes such as cerebral palsy, stroke, or multiple sclerosis (MS). Functional electrical stimulation of the peroneal nerve has been suggested for these patients as an aid in raising the toes during the swing phase of ambulation. In these devices, a pressure sensor detects heel off and initial contact during walking. A signal is then sent to the stimulation cuff, initiating or pausing the stimulation of the peroneal nerve, which activates the foot dorsiflexors. Examples of such devices used for treatment of footdrop are the Innovative Neurotronics's (formerly NeuroMotion Inc.) WalkAide®, Bioness' radiofrequency controlled NESS L300™, and the Odstock Foot Drop Stimulator. An implantable peroneal nerve stimulator system (ActiGait) is being developed in Europe.

Another application of functional electrical stimulation is to provide spinal cord-injured patients with the ability to stand and walk. Generally, only spinal cord injury patients with lesions from T4 to T12 are considered candidates for ambulation systems. Lesions at T1 to T3 are associated with poor trunk stability, while lumbar lesions imply lower-extremity nerve damage. Using percutaneous stimulation, the device delivers trains of electrical pulses to trigger action potentials at selected nerves at the quadriceps (for knee extension), the common peroneal nerve (for hip flexion), and the paraspinals and gluteals (for trunk stability). Patients use a walker or elbow-support crutches for further support. The electrical impulses are controlled by a computer microchip attached to the patient's belt that synchronizes and distributes the signals. In addition, there is a finger-controlled switch that permits patient activation of the stepping.

Other devices include a reciprocating gait orthosis with electrical stimulation. The orthosis used is a cumbersome hip-knee-ankle-foot device linked together with a cable at the hip joint. The use of this device may be limited by the difficulties in putting the device on and taking it off.

Neuromuscular stimulation is also proposed for motor restoration in hemiplegia and treatment of secondary dysfunction (e.g., muscle atrophy and alterations in cardiovascular function and bone density) associated with damage to motor nerve pathways.

Functional NMES is a method being developed to restore function to patients with damaged or destroyed nerve pathways (e.g., stroke, spinal cord injury, multiple sclerosis, cerebral palsy) through use of an orthotic device with microprocessor-controlled electrical stimulation. Evidence for neuromuscular stimulation to provide functional movement in patients with spinal cord injury is limited by the small number of subjects studied to date. For chronic poststroke footdrop, a large randomized controlled trial and crossover study of NMES versus ankle-foot orthosis (AFO) show improved satisfaction with NMES but no change in objective measures of walking. A small randomized trial examining neuromuscular stimulation for footdrop in patients with MS showed a reduction in falls and improvement in satisfaction when compared with a program of exercise, but did not demonstrate a clinically significant benefit in walking speed. The literature on NMES in children with cerebral palsy includes a systematic review of small studies with within-subject designs; additional study in a larger number of subjects is needed. Due to insufficient evidence for some indications, and a lack of improvement for others, functional NMES remains not medically necessary.

The Centers for Medicare and Medicaid Services (CMS) states that NMES to treat muscle atrophy is limited to the treatment of disuse atrophy where nerve supply to the muscle is intact, including brain, spinal cord, and peripheral nerves. It is also used for other non-neurological reasons for disuse atrophy. Some examples would be casting or splinting of a limb, contracture due to scarring of soft tissue (as in burn lesions), and hip replacement surgery (until orthotic training begins).

FES is limited to SCI patients for walking, who have completed a training program consisting of at least 32 physical therapy sessions with the device over a period of three months. The physical therapy trial period is necessary for the treating physician to accurately assess the patient's ability to use the devices frequently and over a long period of time. Physical therapy, necessary to perform this training, must be directly performed by the physical therapist as part of a one-on-one training program. The goal of physical therapy must be to train SCI patients on the use of FES devices to achieve walking, not to reverse or retard muscle atrophy.

Therapists with sufficient support skills are only allowed to provide these services in the following settings: inpatient hospitals, outpatient hospitals, comprehensive outpatient rehabilitation facilities, and outpatient rehabilitation facilities.

### **CODING**

The following HCPCS Codes are covered for BlueCHiP for Medicare members only when medical criteria above is met and not medically necessary for commercial products:

**E0764** Functional neuromuscular stimulation, transcutaneous stimulation of sequential muscle groups of ambulation with computer control, used for walking by spinal cord injured, entire system, after completion of training program

**E0770** Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified

### **RELATED POLICIES**

Prior Authorization via Web-Based Tool for Durable Medical Equipment (DME)

### **PUBLISHED**

Provider Update, July 2020

Provider Update, August 2019

Provider Update, November 2018

Provider Update, October 2017

Provider Update, May 2016

### **REFERENCES**

1. Centers for Medicare and Medicaid Services: National Coverage Determination for NEUROMUSCULAR ELECTRICAL Stimulator (NMES) (160.12) Accessed 11/16/11  
[http://www.cms.gov/mcd/viewncd.asp?ncd\\_id=160.12&ncd\\_version=2&basket=ncd%3A160%2E12%3A2%3ANeuromuscular+Electrical+Stimulator+%28NMES%29](http://www.cms.gov/mcd/viewncd.asp?ncd_id=160.12&ncd_version=2&basket=ncd%3A160%2E12%3A2%3ANeuromuscular+Electrical+Stimulator+%28NMES%29)
2. Triolo, R. PhD, et al (2001). Selectivity of intramuscular stimulating electrodes in the lower limbs[Electronic version]. Journal of Rehabilitation Research & Development, v38,5, Sept/Oct.
3. Prosser LA, Curatalo LA, Alter KE et al. Acceptability and potential effectiveness of a foot drop stimulator in children and adolescents with cerebral palsy. Dev Med Child Neurol 2012;54(11):1044-9
4. Meilahn JR. tolerability and Effectiveness of a Neruoprosthesis for the treatment of Footdrop in Pedicatic Patients With Hemiparetic Cerebral Palsy.PMR2013
5. Nash MS, Jacobs PL, Montalvo BM et al. Evaluation of a training program for persons with SCI paraplegia using the Parastep 1 ambulation system: part 5. Lower extremity blood flow and hyperemic responses to occlusion are augmented by ambulation training. Arch Phys Med Rehabil 1997; 78(8):808-14.

6. Rohde LM, Bonder BR, Triolo RJ. Exploratory study of perceived quality of life with implanted standing neuroprostheses. *J Rehabil Res Dev* 2012; 49(2):265-78
7. Triolo RJ, Bailey SN, Miller ME et al. Longitudinal performance of a surgically implanted neuroprosthesis for lower- extremity exercise, standing, and transfers after spinal cord injury. *Arch Phys Med Rehabil* 2012; 93(5):896-904.
8. Everaert DG, Stein RB, Abrams GM et al. Effect of a foot-drop stimulator and ankle-foot orthosis walking performance after stroke: a multicenter randomized controlled trial. *Neurorehabil Neural Repair* 2013; 27(7):579-91.
9. Bethoux F, Rogers HL, Nolan KJ, et al. The effects of peroneal nerve functional electrical stimulation versus ankle-foot orthosis in patients with chronic stroke: a randomized controlled trial. *Neurorehabil Neural Repair*. Sep 2014;28(7):688-697. PMID 24526708
10. O'Dell MW, Dunning K, Kluding P, et al. Response and prediction of improvement in gait speed from functional electrical stimulation in persons with poststroke drop foot. *PM&R*. Jul 2014;6(7):587-601; quiz 601. PMID 24412265
11. Bethoux F, Rogers HL, Nolan KJ, et al. The effects of peroneal nerve functional electrical Stimulation versus ankle-foot orthosis in patients with chronic stroke: a randomized controlled trial. *Neurorehabil Neural Repair*. Sep 2014;28(7):688-697. PMID 24526708
12. O'Dell MW, Dunning K, Kluding P, et al. Response and prediction of improvement in gait speed from functional electrical stimulation in persons with poststroke drop foot. *PM&R*. Jul 2014;6(7):587-601; quiz 601. PMID 24412265



[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

